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ABSTRACT
Common fragile sites (CFSs) are conserved genomic
regions prone to break under conditions of replica-
tion stress (RS). Thus, CFSs are hotspots for rear-
rangements in cancer and contribute to its chromo-
somal instability. Here, we have performed a global
analysis of proteins that recruit to CFSs upon mild
RS to identify novel players in CFS stability. To this
end, we performed Chromatin Immunoprecipitation
(ChIP) of FANCD2, a protein that localizes specifi-
cally to CFSs in G2/M, coupled to mass spectrome-
try to acquire a CFS interactome. Our strategy was
validated by the enrichment of many known regula-
tors of CFS maintenance, including Fanconi Anemia,
DNA repair and replication proteins. Among the pro-
teins identified with unknown functions at CFSs was
the chromatin remodeler ATRX. Here we demonstrate
that ATRX forms foci at a fraction of CFSs upon RS,
and that ATRX depletion increases the occurrence
of chromosomal breaks, a phenotype further exacer-
bated under mild RS conditions. Accordingly, ATRX
depletion increases the number of 53BP1 bodies and
micronuclei, overall indicating that ATRX is required
for CFS stability. Overall, our study provides the first
proteomic characterization of CFSs as a valuable re-
source for the identification of novel regulators of
CFS stability.
INTRODUCTION
Common fragile sites (CFSs) are chromosomal regions
highly susceptible to break, and thus pose a serious threat to
genomic integrity (1). These genomic regions are present in
all individuals and can give rise to chromosomal abnormal-
ities, including small deletions and insertions, and translo-
cations (2,3). This genomic instability that arises at CFSs is
a hallmark of cancer, and can indeed be observed in early
stages of tumorigenesis (4,5). Several properties of CFSs
contribute to the fragile nature of these genomic regions.
First, many CFSs harbor long genes, such as FHIT (in
FRA3B) and WWOX (in FRA16D), increasing the prob-
ability of collision between the replication and transcrip-
tion machineries, which may ultimately result in replication
fork collapse (6–10). Second, some CFSs contain few repli-
cation origins, requiring replication forks to cover longer re-
gions and rendering fewer opportunities to rescue replica-
tion upon replication stress (RS) or fork stalling (11). Third,
someCFSs encompass repetitive sequences and regions that
are particularly A-T rich, which can form secondary DNA
structures, further complicating DNA replication and thus
contributing to fragility (12). Moreover, it is well-known
that CFSs complete replication very late in S-phase (13),
limiting the time available to repair challenged CFSs prior
to mitosis, thereby further increasing their fragility. Impor-
tantly, these inherent complications of replicating CFSs are
exacerbated in conditions of mild RS which occurs upon
oncogenic transformation or experimentally with low doses
of the polymerase inhibitor aphidicolin (APH), that slows
down replication (13–15).
The factors that have been implicated in CFS mainte-
nance and repair are largely known from other DNA repair
pathways, including double strand break (DSB) repair (i.e.
ATM,MRN complex and BRCA1) (16,17) the RS response
(CHK1 and ATR) (18,19) and interstrand crosslink repair,
such as the Fanconi Anemia proteins (20). Despite these de-
fense mechanisms, some perturbed CFSs are not resolved
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in a timely manner. Consequently, upon entry into mitosis,
a next line of defense is set in motion, involving cleavage
of the CFSs by MUS81-EME1 endonuclease to permit mi-
totic DNA synthesis (MiDAS) and thereby completion of
CFS replication (21). Occasionally, all lines of defense fail,
resulting in chromosomal aberrations that are transmitted
to daughter cells, and can give rise to pathological condi-
tions such as cancer. Given the hazards that these fragile re-
gions can pose, and their ubiquitous nature in human cells,
the study of novel factors regulating CFS stability may in-
crease the understanding of the diseases in which they are
involved.
Typically, studies of CFS maintenance proteins have
been restricted to hypothesis driven approaches using
immunofluorescence-based (IF) techniques, which are lim-
ited by the availability of specific antibodies. In this study,
we aimed to characterize the proteins that localize to CFSs
using an unbiased approach, in order to identify novel play-
ers that regulate CFS stability. To this end, we took advan-
tage of the latest OrbitrapMass Spectrometry (MS) (22) de-
velopments in combination with chromatin immunoprecip-
itation (ChIP) of FANCD2, to map the proteins that are
recruited to CFSs when challenged. FANCD2 is a DNA re-
pair protein from the Fanconi Anemia pathway that local-
izes to challenged CFSs in G2 and mitosis (23,24), and is
essential to ensure their efficient replication (25). By com-
bining the FANCD2 ChIP with stable isotope labeling of
amino acids in cell culture (SILAC) (26) for accurate quan-
tification, we generated the first map of the CFS proteome.
Using this quantitative interaction proteomics approach,
we identified many proteins that are already known to play
a role in CFS maintenance, including factors involved in
chromosome organization, DNA replication and DNA re-
pair. Furthermore, we mapped proteins which, to date, are
uncharacterized in the context of CFS regulation. Of the
prominent and unknown CFS associated proteins, we char-
acterized the role of the chromatin remodeler ATRX. Our
study demonstrates that ATRX localizes to a subset of
CFSs, and is relevant to prevent CFS instability. Overall, we
believe that our approach and the resource that we provide
in this studywill serve as a platform for future investigations
to gain insights into the biology of these poorly character-
ized genomic regions.
MATERIALS AND METHODS
Cell culture
HeLa cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) (GIBCO) supplemented with 10% fe-
tal bovine serum (FBS) (Life Technologies) and 1% of
penicillin/streptomycin (Life Technologies). For the pro-
teomics experiments, HeLa S3 were used as HeLa is telom-
erase positive, and these suspension cells facilitated cultur-
ing of the large number of cells required for ChIP-MS. For
SILAC labeling (26), HeLa S3 were grown in SILACRPMI
(Roswell Park Memorial Institute) 1640 media (Biowest)
supplemented with 10% dialyzed FBS (Sigma), 100 g/ml
penicillin (Invitrogen), 100 g/ml streptomycin (Invitro-
gen), 2 mM L-glutamine (Gibco) and one of the follow-
ing three labeling combinations: (i) natural light variants of
the amino acids (Lys0, Arg0) (Sigma); (ii) medium variants
of amino acids {L-[2H4]Lys (+4) and L-[13C6]Arg (+6)}
(Lys4, Arg6) and (iii) heavy variants of the amino acids {L-
[13C6,15N2]Lys (+8) and L-[13C6,15N4]Arg (+10)} (Lys8,
Arg10). Medium and heavy variants of amino acids were
purchased from Cambridge Isotope Laboratories. This
medium will henceforth be referred to SILAC RPMI. All
cell lines were maintained at 37◦C in a 5% CO2 incubator.
Cell synchronization
For MS experiments, asynchronous medium and heavy la-
beled HeLa S3 cells were arrested in G2/M by 16 h treat-
ment with 4 mM thymidine (Sigma, T9250), followed by
7.5 h release into fresh SILAC RPMI, which is thereafter
supplemented with 100 g/l nocodazole (Sigma,M1404),
with or without APH (0.2 M) (Sigma, A0781) or DMSO
(Sigma, D2438) for 20 h. For pilot experiments thymidine
was used at 2 mM, nocodazole treatment was for 16 h, and
APH at 0.4 M.
Flow cytometry analysis
HeLa S3 cells were harvested by centrifugation (400× g for
4 min) and washed once with 1× PBS. Subsequently cells
were fixed with 70% ice-cold ethanol and incubated for at
least 30 min at 4◦C. Fixed cells were washed two times with
1% BSA in PBS and incubated with 100 g/ml ribonucle-
ase A (Sigma, R6513) and propidium iodide (20 g/ml)
(Sigma, P4864) at 37◦C for 1 h. DNA content was deter-
mined by flow cytometry with Fortessa 3 lasers (BD Bio-
sciences) and the analysis was performed with the Flowjo
software.
ChIP for MS analysis
SILAC-labeled HeLa S3 cells were grown and synchro-
nized accordingly to the synchronization protocol described
above. After synchronization ∼70 × 106 cells were used
for each ChIP experiment. Cells were harvested by cen-
trifugation for 3 min (900 × g) and washed three times
with ice cold PBS. Cells were permeabilized in ice cold
0.2% Triton X-100 (Sigma, T8787) in PBS supplemented
with protease inhibitor (complete inhibitor cocktail tablet)
(Roche) for 5 min on ice. Subsequently, cells were pelleted,
washed twice with ice cold PBS and cross-linked in 4%
formaldehyde (VWRChemical) for 15 min at room temper-
ature (RT). Cross-linked cells were washed twice with ice
cold PBS and resuspended in lysis buffer (150 mM NaCl,
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 25 mM
Tris–HCl and 5 mM EDTA) supplemented with 5 mM -
glycerolphosphate, 5 mM NaF, 1 mM sodium orthovana-
date and complete inhibitor cocktail tablet (Roche). Sam-
ples were sonicated using a Bioruptor® Pico (Diagenode
B01060010) for chromatin fragmentation. Briefly, samples
were collected in microcentrifuge tubes containing 50 mg
of beads (provided by Diagenode for sonication) and son-
icated at 4◦C for 40 cycles with 30 s on and 30 s off. 4 g
of FANCD2 (NB100–182SS) or control rabbit IgG (Sigma-
Aldrich) antibody was added to cell lysates and the mix-
ture was incubated for 2 h with rotation at 4◦C. Chromatin
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/47/15/8004/5513321 by R
oyal Library C
openhagen U
niversity user on 28 O
ctober 2019
8006 Nucleic Acids Research, 2019, Vol. 47, No. 15
bound to the antibody was then immunoprecipitated us-
ing 60 l of protein G agarose beads slurry (Pierce™ 20398)
which had been washed three times in lysis buffer. Samples
were immunoprecipitated overnight with rotation at 4◦C.
The beads were pelleted and washed once with lysis buffer,
and the three samples corresponding to the three different
SILAC conditions were pooled. Subsequently, beads were
washed three times with lysis buffer, crosslinking was re-
versed and proteins were eluted with 4% SDS, 25 mM Tris
supplemented to 100 mM dTT for 1 h at 95◦C.
In gel digestion
The eluted proteins were separated by SDS-page on Nu-
Page 4–12% Bis–Tris protein Gel (Novex, Thermo Fisher
Scientific). The proteins were visualized by coomassie us-
ing the Colloidal Blue Staining Kit (Invitrogen). Gel bands
were cut, destained (50% ethanol in 25 mM ammonium bi-
carbonate (ABC)) and dehydrated in 96% ethanol. Subse-
quently, the samples were incubated with 10 mM DTT (in
25 mM ABC) for 30 min, followed by 30 min incubation
with 55 mM CAA (in 25 mM ABC). After two washes in
25 mMABC, and dehydration (in 96% ethanol) proteolysis
was performed with trypsin (Sigma) (1.5 g/ml) overnight.
Trypsin activity was quenched with trifluoroacetic acid
(TFA) at a final concentration of 1%. The eluate was col-
lected, and the gel pieces were sequentially incubated with
Washing solution A (30% (v/v) acetonitrile (ACN), 3%
(v/v) TFA in milliQ), Washing solution B (80% (v/v) ACN,
0.5% (v/v) acetic acid in milliQ) and finally with 100%
ACN. Samples were collected after incubation with each
buffer for 30 min. The ACN was removed by vacuum cen-
trifugation and the resulting peptides were loaded on C-18
STAGE-tips (27). Stagetipping was performed as (28).
Nanoflow LC–MS/MS
For LC–MS/MS analysis, peptides were eluted from
STAGE-tips with 40% ACN in 0.5% formic acid, ACN was
removed by vacuum centrifugation and the peptides were
reconstituted in 5% ACN, 1%TFA. Peptides were analyzed
with an Easy-nLC 1000 system coupled to the Q Exac-
tive HF-X instrument (Thermo Fisher Scientific) through
a nanoelectrospray ion source. Peptide separation was per-
formed on an analytical column (inner diameter 75 m),
with 1.9 m C18 beads (Dr Maisch, packed in-house), at
40◦C with an integrated column oven (PRSO-V1, Sonation
GmbH). The peptides were eluted on a 15 cm column over
30 min at a flow rate of 350 nl/min from 10% to 80% buffer
B (80% ACN, 0.5% formic acid). MS data was acquired in
data-dependent mode (DDA), with positive polarity and
30 s dynamic exclusion window. Full scans were acquired
with 60 000 resolution, at 350–1400 m/z scan range, with
an ion target value of 3e6 and 45 s maximum injection time.
MS/MS were acquired with a top 6 method, scans were ac-
quired at 30 000 resolution, with a ion target of 1e5 and
scan range of 200–2000 m/z. All fragmentation was per-
formed in parallel acquisition with higher-collision dissoci-
ation (HCD). Samples from the pilot experiment were ana-
lyzed on a Q-Exactive HF, using a top 10 method, with fulls
scans acquired at 120 000 resolution, maximum injection
time of 20 ms, at a scan range of 300–1750 m/z. MS/MS
scans were acquired at 60 000, ion target value of 2e5, max-
imum injection time of 110 ms.
Database search and quantification
All raw LC–MS/MS files were analyzed in the MaxQuant
software suite v. 1.6.0.1 (29), with the integrated database
search engine Andromeda (30), against the Uniprot
database. Common contaminants were included in the
database and excluded upon data analysis. Searches were
performed with the match between runs options. Cystein
carbidomethylation was set as a fixed modification, while
methionine oxidation and N-terminal acetylation were set
as variable modifications. False discovery rate was set to 1%
for peptide spectral matches (PSMs) and protein level, cal-
culated using the decoy database strategy.
Bioinformatics analysis of MS data
We required that all proteins groups were identified with at
least two peptides for inclusion in further analysis. GO term
enrichment analysis was performed using DAVID database
(31,32) and the enrichment was calculated against the hu-
man genome as reference. Functional network analysis was
mapped using the STRING database in Cytoscape (33), re-
quiring a minimum confidence score of 0.4.
RNA interference
HeLa cells were reverse-transfected in DMEM supple-
mented with 10% FBS with the indicated siRNAs us-
ing DharmaFECT 1 transfection reagent (Dharmacon, T-
2001-01) and following the manufacturer’s instructions.
The media was changed the day after transfection. The
final siRNA concentration used was 20 nM and exper-
iments were performed 72 h after transfection. The se-
quences of the sense strand of siRNA duplexes are UA
ACGACGCGACGACGUAA (siCtrl#1 control 1); CGUA
CGCGGAAUACUUCGA (siCtrl#2, control 2); CAAU
GGUAUUGCUACAUUU (siATRX#1); GUGGGCUG
AAGAAUUUAAU (siATRX#2); GCACCGUAUUCA
AGUACAA (siFANCD2#1); GAUAAGUUGUCGUC
UAUUA (siFANCD2#2); CGUGCCCACUCUCUGU
UUU (siDAXX#1); CAGAAACAUUAAUAAACAAUA
(siDAXX#2).
Western blotting
To obtain protein extracts for SDS-PAGE, cells were lysed
in RIPA Buffer (Sigma, R0278) supplemented with com-
plete protease inhibitor cocktail tablet (Roche), 5 mM -
glycerolphosphate, 5 mM NaF and 1 mM sodium or-
thovanadate. Protein quantification was performed with
the DC Protein Assay kit (Bio-Rad). Protein samples
were boiled in NuPAGE™ LDS Sample Buffer 4x (Novex,
NP0007) with 10 mM DTT at 70◦C and separated with 4–
12% NuPage Bis–Tris gels (Novex, NP0321). Proteins were
transferred to a PVDF membrane, subsequently blocked
with 5% skimmed milk in PBST (PBS supplemented with
0.1% Tween-20) for 1 h at RT and thereafter incubated
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with primary antibodies overnight at 4◦C. On the follow-
ing day, membranes were washed in PBST, incubated with
the appropriate HRP-conjugated secondary antibodies for
1 h at RT, then washed and developed using AmerSham™
ECL™ Western Blotting Detection Reagents (GE Health-
care, RPN2106). Chemiluminescence detection was done
with an AmerSham™ Imager 600. The primary antibod-
ies used were mouse monoclonal ATRX (Santa Cruz, sc-
55584) and mouse vinculin (Sigma, V9131).
Immunofluorescence and high content microscopy
For immunofluorescence (IF) assays, 5000 cells were seeded
on CLEAR 96-well plates (Greiner Bio-One, 655090) for
high content imaging, or on coverslips. The cells were pre-
extracted with ice cold 0.2% Triton X-100 (Sigma, T8787)
in PBS for 1 min on ice and then fixed with 4% formalde-
hyde (VWR Chemicals) for 15 min at RT. For immunos-
taining of 53BP1/Cyclin-A, cells were directly fixed with
4% formaldehyde for 15 min RT and then permeabilized
with 0.5% Triton X-100 in PBS for 10 min. Cells were
washed and blocked with 2.5% BSA (Sigma, A7030) in
PBST for 30min and then incubated with primary antibody
at 4◦C overnight. On the following day, wells were washed
in PBST, fluorescence-tagged secondary antibody (Alexa
Fluor™ Goat Anti-mouse IgG 488 (Invitrogen, A11001);
Alexa Fluor™ Chicken anti-Rabbit IgG 647 (Invitrogen,
A21443)) added for 2 h at RT in the dark and stained
with DAPI for 10 min. The primary antibodies used were
ATRX (Santa Cruz, sc-55584), FANCD2 (Novus Biologi-
cals, NB100-182), 53BP1 (Novus Biologicals, 100-304A2),
Cyclin A (Abcam, ab16726) and DAXX (Bethyl Laborato-
ries, A301-353A). For EdU (Life Technologies, A10044) in-
corporation analysis, EdU was added 30 min prior to fixing
the cells and click chemistry done prior to blocking. A di-
lution of 10 mM ascorbic acid was prepared fresh, and the
click-it reactionmix was performed by adding PBS, CuSO4,
Az. 647 and ascorbic acid in given order which was then
added to each well for 1 h RT in the dark. Images were ac-
quired using an Olympus IX-83 or for high content imag-
ing the ScanR acquisition software (Olympus) controlling a
motorized Olympus IX-81 wide-field microscope. Olympus
UPLSAPO 10×/0.4 NA and 40x/0.9 NA objectives were
used. For counting of foci, z-stack imageswere acquired and
the ScanR analysis software (Olympus) was used to count
the total number of foci per cell.
Preparation and analysis of chromosome spreads
HeLa cells seeded in 10-cm dishes were transfected with
indicated siRNAs. Two days post transfection cells were
treated with DMSO (Sigma, D2438) or APH (0.4 M)
(Sigma, A0781) for 20 h. Colcemid (0.1 g/ml) (Ther-
moFisher Scientific, 15210-040) was added 5 h prior to col-
lection of samples. Cells were harvested and collected in a 15
ml tube. After centrifugation for 5 min (300 x g), the super-
natant was removed, the pellet was carefully resuspended
and 5 ml of pre-warmed (37◦C) 75 mM KCl (Sigma) was
added drop-by-drop. The cell suspension was then incu-
bated for 20 min at 37◦C. Swollen cells were collected by
centrifugation for 6 min (300 x g) and resuspended with
5 ml of fixation solution methanol:acetic acid (3:1) added
drop-by-drop while vortexing carefully. Fixed cells were in-
cubated at RT for 30 min followed by at least 1 h at –20◦C.
For preparation of chromosome spreads, cells were dropped
on humid slides and air dried overnight. On the following
day, slides were washed with PBS for 30 min and chromo-
somes stained using DAPI (Vectashield; Vector Labs). Im-
ages were captured using an Olympus BX63 microscope us-
ing 60X/OIL objective. The criteria for scoring breaks and
gaps were as in (34).
Analysis of MiDAS on chromosome spreads
HeLa cells seeded in 10-cm dishes were transfected with
indicated siRNAs. Two days post transfection, cells were
treated with DMSO (Sigma, D2438) or APH (0.4 M)
(Sigma, A0781) for 20 h and RO-3306 (7 M) (Sigma,
SML0569) was added for the last 6 h. Cells were subse-
quently washed twice with pre-warmed PBS, once with pre-
warmed DMEM and released into media containing EdU
(20M)and colcemid (0.1g/ml) for onemore hour. Chro-
mosome spreads were prepared as described in the sec-
tion above. For EdU Click-IT reaction, slides were fixed
with 4% formaldehyde for 11 min and blocked three times
with PBS containing 4% BSA for 10 min. Subsequently,
EdU detection was performed by using Click-IT Plus EdU
Alexa Fluor 594 Imaging Kit following manufacturer’s in-
structions (Thermo Fischer Scientific). Chromosomes were
stained using DAPI (Vectashield; Vector Labs) and images
were captured with an Olympus BX63 microscope using
60×/oil objective.
Fluorescence in situ hybridization (FISH)
Chromosome spreads were prepared as described above.
FRA16D FISH probe was prepared from the BAC clone
RP11-264L1 (GenBank:AC046158.6) and labeled using the
BioNick labeling system (Thermo Fisher Scientific). Chro-
mosome spreads were dehydrated in an ethanol series (70%,
90%, 99%) at RT for 2 min each. Samples were denatured in
70% formamide at 75◦C for 2.5 min and dehydrated again
with ice-cold ethanol series (70%, 90%, 99%) for 2min each.
FISH probe was denatured at 93◦C for 5min and hybridiza-
tion was performed at 37◦C for 72 h. Biotin-conjugated
probe was detected using avidin-FITC (Thermo Fisher Sci-
entific) and biotin-labeled anti-avidin (Vector Labs). Chro-
mosomes were stained using DAPI (Vectashield; Vector
Labs) and images were capturedwith anOlympus BX63mi-
croscope using 60×/oil objective.
Immunofluorescence combined with FISH
For experiments where IF was combined with FISH, HeLa
cells were treated with DMSO (Sigma, D2438) or APH (0.4
M) (Sigma, A0781) for 20 h and 6 M RO-3306 (Sigma,
SML0569) was added for the last 6 h of treatment to arrest
cells in G2. Cells were harvested with trypsin and seeded
on slides using a Cytospin 4 cytocentrifuge (Thermo Fisher
Scientific). Samples were pre-extracted and fixed with 4%
formaldehyde (VWR Chemical) and 0.2% Triton X-100
(Sigma, T8787) in cold PBS for 20 min at 4◦C. Slides were
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washed in PBS andATRX IFwas performed as described in
the IF method section. Prior to FISH experiments, samples
were re-fixed with 4% formaldehyde. For FISH, samples
were dehydrated in an ethanol series (70%, 90%, 99%) at
RT for 2 min each, and samples were denatured at 90◦C for
5 min. Hybridization and detection was performed as de-
scribed above. Cells were stained using DAPI (Vectashield;
Vector Labs) and images were captured with an Olympus
BX63 microscope using 60×/oil objective.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
7 using the unpaired t-test method for significance testing.
To validate that ATRX and FANCD2 foci colocalization
changes upon APH treatment were not product of chance
we used the JACoP plugin for FIJI (35). To assess signif-
icance of FRA16D breakage in chromosome spreads we
used the chi-square statistical test.
RESULTS
Quantitative MS-based approach for identification of CFS
interacting proteins
To identify new regulators of CFS stability, we developed
a workflow to perform global analysis of CFS binding
proteins using SILAC-based quantitative MS (26). Our
methodology is based on the enrichment of chromatin as-
sociated to FANCD2, a protein that has been described
to localize specifically to CFS in G2/M cells (23) (Figure
1A). Critically, we used telomerase-positive HeLa S3 cells
to avoid the enrichment of telomeric regions, as FANCD2
also localizes at telomeres in ALT-positive cell lines (36). To
create conditions of mild RS that mimic those of oncogenic
transformation and that cause CFS instability, we treated
the cells with low doses of APH (0.2–0.4 M). These con-
ditions increase the number of challenged CFSs harboring
FANCD2 in G2/M (23) and are typically used to study
the mechanisms and proteins that resolve CFS aberrations
(21,23,37,38). Additionally, to enhance the number of cells
with FANCD2 localized at CFSs, cells were synchronized
in G2/M. Briefly, cells were blocked at the G1/S boundary
with thymidine for 16 h, followed by 7.5 h release into S
phase and finally arrested at prometaphase by 20 h nocoda-
zole treatment with or without APH to increase the num-
ber of challenged CFSs (Figure 1A). The synchronization
efficiency was evaluated by cell cycle distribution analysis
using flow cytometry, to confirm that indeed the majority
of cells were in G2/M (Figure 1B). The cell cycle profiles
obtained were similar in medium and heavy SILAC labeled
cells, which were both synchronized and treated with APH,
while the light-labeled cells were maintained asynchronous
and without APH treatment (Figure 1B).We validated that,
in accordance with the literature, the APH treatment exac-
erbated the number of FANCD2 foci in G2/Mcells, and us-
ing EdU (5-Ethynyl-2′-deoxyuridine) as a marker of ongo-
ing replication we confirmed that these foci were late repli-
cating sites and thereby CFSs (23) (Figure 1C). Finally, to
enrich proteins associated with these challenged CFSs, we
performed aChIP of endogenous FANCD2 after extraction
of the soluble fraction by permeabilization and subsequent
crosslinking with formaldehyde (Figure 1A). IgG was used
for ChIP from the medium labeled condition to allow as-
sessment of background interactors in the FANCD2 pull-
down (Figure 1A).
After immunoprecipitation, formaldehyde crosslinks
were reversed and proteins were separated by SDS-page
followed by in-gel digestion prior to state-of-the-art nano
liquid-chromatography tandem-MS (LC-MS/MS) analysis
on a Q-Exactive HF-X orbitrapmass spectrometer (22). All
raw LC–MS/MS files from two biological replicates were
processed and analyzed together in the MaxQuant soft-
ware suite (29) (www.maxquant.org) using the integrated
database search engine, Andromeda, with a 1% false discov-
ery rate at the peptide and protein levels (30). The database
search was performed together with raw files from a pilot
experiment where different cell cycle profiles were obtained
from a separate synchronization protocol (Supplementary
Figures S1A and B). Only the medium (+APH, IgG ChIP)
and heavy (+APH, FANCD2 ChIP) conditions from the
pilot experiment were used for some downstream analysis.
With this workflow, we performed a global analysis of pro-
teins associated with FANCD2-enriched CFSs.
Global analysis of the CFS interactome
To discriminate background binders from proteins that are
associated with CFSs in our MS-based workflow, we strat-
ified the protein groups identified in the database search
by applying quantitative filters and validating the results
with bioinformatics tools. The database search identified
894 protein groups, of which 665 were identified with more
than one peptide and used for downstream analysis (Fig-
ure 2A and Supplementary Table S1). For potential CFS
interactors we further required at least 1.5-fold higher abun-
dance in the FANCD2 pull-down compared to IgG from
synchronized andAPH treated cells inmore than half of the
experiments fromwhich theywere identified.With these cri-
teria, we categorized 226 potential CFS interactors, with the
bait itself, FANCD2, and its constitutive interactor FANCI
among the most enriched in the FANCD2 IP compared
to IgG (Supplementary Figure S2A and Table S2). To de-
termine whether these 226 proteins represented a group
of identifications relevant for CFS stability, we performed
Gene Ontology (GO) enrichment analysis. We found that
these proteins were primarily located at chromosome re-
lated compartments, and they were highly enriched for fac-
tors involved in DNA repair and chromosome organization
as expected for CFS related proteins where these biological
processes are central for maintaining CFS stability (Figure
2B).
To visualize the potential CFS interacting proteins, we
performed a functional network analysis and grouped the
proteins according to their known functions (Figure 2C).
Notably, many proteins with known functions in mainte-
nance of CFS stability were found to be highly enriched.
Among these, FANCD2, FANCI and other proteins of the
Fanconi Anemia complex were highly enriched, including
APITD1, also known as CENPS, which promotes mono-
ubiquitination of FANCD2-FANCI in response to DNA
damage (39). We also found RBPP8, known as CtIP, and
all the proteins of the MRN complex (Mre11, Rad50 and
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Figure 1. Workflow for MS-based quantification of CFS associated proteins. (A) Experimental workflow for SILAC-based quantitative MS identification
of CFS associated proteins. (B) Flow cytometry analysis of cell cycle distribution of SILAC labeled cells used for enrichment of CFSs as illustrated in (A).
(C) IF of FANCD2 and EdU incorporation to assess formation of FANCD2 foci at late replicating regions with and without APH treatments. Cells were
synchronized as in (A) and (B).
Nbs1) to be highly enriched. Importantly, the nuclease ac-
tivities of Mre11 and CtIP have been shown to be required
for DSB repair at CFSs (40). Furthermore, TOP3A, RMI1
and RMI2, which form the TRR complex that associates
with BLM, and other proteins with well-established roles in
the processing of challenged CFSs were found to be highly
enriched (41–43). We also quantified a high enrichment of
PCNA, components of the MCM helicase, and other repli-
cation proteins, which are associated with chromatin in mi-
totic cells upon RS (21), and would expectedly be enriched
at CFSs with stalled replication forks. The data demon-
strates that the proteomics-based workflow we developed,
in combination with the analysis approach applied, is a
powerful strategy to identify CFS associated proteins.
Notably, our data also showed a high enrichment of small
ubiquitin like modifier (SUMO), a post-translational mod-
ification that is known to regulate protein functions at the
chromatin in response to DNA damage and RS (44–47)
(Figure 2C).
To date, the majority of the proteins involved in main-
tenance of CFS stability are established players in path-
ways contributing to safeguarding genomic stability, such
as those responding to DSBs and RS. Notably, our data
shows a strong enrichment for these categories of proteins,
supporting that this data is a valuable resource to identify
new regulators with a particular role in CFS maintenance.
ATRX is associated with chromatin under conditions that in-
duce CFS expression
Next, we identified the proteins that are recruited to chal-
lenged CFSs specifically upon perturbation of replication
with APH. For this, we required that proteins deemed as
potential CFS interactors (as defined above) were also en-
riched at least 1.5-fold in the FANCD2 pull-down from syn-
chronized cells treated with APH (heavy) compared to un-
treated asynchronous cells (light) (Figure 2A). This resulted
in a selective dataset of 45 proteins (diamond shaped nodes
in Figure 2C and Supplementary Table S3), of which the
top 20 are listed in Supplementary Figure S2. This subset
of proteins is largely comprised of factors with known in-
volvement in DNA repair, and proteins known to function
in CFS stability, including FANCD2, FANCI, BLM and
BRCA1 (Figure 2C) (16,20,43). Therefore, we consider that
this dataset could also contain a number of proteins with
uncharacterized functions at CFSs. Among these, we val-
idated and characterized ATRX, a SNF-2 type chromatin
remodeler, due to its previously defined functions and its
known role as tumor suppressor (48). As such, ATRX has
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Figure 2. Overview and analysis of MS-based identification of CFS associated proteins. (A) Results and filtering of identifications from MS analysis. (B)
GO term enrichment analysis for biological process and cellular localization within the 226 proteins that were more abundant in the FANCD2 pull-down
compared to IgG. Analysis was performed using theDAVID tool with the human genome as reference. (C) Functional network analysis of all 226 FANCD2
enriched proteins. The color of the nodes indicates the level on enrichment in the FANCD2 pull-down compared to IgG. Diamond shaped nodes indicate
those that were enriched in the FANCD2 pull-down fromAPH treated cells compared to vehicle treated. Proteins with well-defined relevant functions have
been grouped. The network was generated using the STRING database in Cytoscape.
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been shown to play an important role in telomere mainte-
nance (49), regions which, similar to CFS, are notoriously
difficult to replicate. Furthermore, ATRX has been impli-
cated in the suppression of DNA–RNA hybrid (R-loop)
stabilization at active transcription sites at telomeric repeats
(50), an alteration that is also found at some CFSs as a con-
sequence of replication-transcription collision.
As a first indication for a potential role for ATRX in the
maintenance of CFS stability, we assessed whether ATRX
forms foci under conditions that provoke CFS instability
(also known as CFS expression). To this end, we treated
HeLa cells with a low dose of APH, and evaluated the for-
mation of ATRX foci by IF combined with high-content
microscopy (Figure 3A). We observed that ATRX forms
discrete foci upon treatment with APH, and that this is in-
creased compared to control cells, indicating that ATRX
responds to perturbed replication (Figure 3A). Next, we
sought to establish whether the formation of ATRX foci
displayed the same pattern as FANCD2 foci, which peaks
in late S and G2 where CFSs are replicating and therefore
challenged, particularly upon APH treatment (Figure 3B).
We treated cells with APH or vehicle, and used labeling
with EdU and DAPI content to profile the different cell
cycle stages (Figure 3B). Similar to FANCD2, the number
of ATRX foci increased from G1 and across the cell cy-
cle, peaking in late S and G2, a phenotype exacerbated at
each stage upon treatment with APH (Figure 3B). Impor-
tantly, to confirm the specificity of ATRX signal obtained
by IF, we knocked-down ATRX with two different siR-
NAs and observed an abrogation of the ATRX foci (Sup-
plementary Figures S3A–C). A number of ATRX foci colo-
calized with FANCD2 in G2 cells upon APH treatment,
where FANCD2 foci served as surrogate markers for CFSs
(Figure 3C and D). Furthermore, the number of colocal-
izing foci increased upon mild RS with APH compared to
untreated G2 cells, indicating that ATRX localizes to chal-
lenged CFSs (Figure 3C and D). We found that in addi-
tion to the fully colocalizing, a number of foci were adja-
cent to each other. As has been observed with other pro-
teins that function in CFSs this pattern could arise due to
different temporal stages of CFS processing (51). Interest-
ingly, we observed that the percentage of FANCD2 foci
colocalizing with ATRX was only mildly increased upon
APH treatment, suggesting that the fraction of stressed
CFSs at which ATRX functions is similar in these condi-
tions (Supplementary Figure S3D). Of note, we could not
detect a direct interaction between ATRX and FANCD2
by co-immunoprecipation experiments (data not shown).
Using the colocalization software JACoP and the Costes
approach (35), we found that the Pearson coefficient for
the colocalization of ATRX and FANCD2 was at least 10-
fold higher in input G2 cell images compared to images
of these same cells where the pixels had been randomized.
These analyses indicate that the colocalization of ATRX
and FANCD2 detected was not by chance with a proba-
bility higher than 99% (data not shown).
To further confirm that a subset of the ATRX foci in G2
is indeed located at CFSs, we performed FISH for FRA16D
combined with ATRX-IF in G2 cells. We observed that
ATRX localized to ∼3% of FRA16D loci in untreated G2
cells, increasing to 7% upon APH treatment (Figure 3E and
F).
Together, these data indicate that ATRX is a novel pro-
tein that localizes to a percentage of challenged CFSs, and
may therefore play a role in maintaining their stability.
ATRX regulates CFS stability
CFS expression is defined by the presence of chromosomal
breaks or gaps inmetaphase spreads from cells that have un-
dergone replication in the presence of low dose ofAPH (14).
Thus, to determine whether the localization of ATRX at a
subset of CFSs plays a role in maintaining CFS stability, we
evaluated the impact of ATRX depletion on chromosome
integrity by studying metaphase spreads.We observed a sig-
nificant increase in the number of chromosomal gaps and
breaks upon depletion of ATRXwith two separate siRNAs
in comparison to control cells (Figure 4A, B and Supple-
mentary Figure S4A). Notably, this increase was observed
in normally proliferating cells, and was exacerbated under
treatment with low dose of APH (Figure 4B), suggesting a
role for ATRX in regulating CFS stability.
To confirm that these sites of breakage were CFSs, we as-
sessed whether these regions were sites of active replication
in mitosis, as it has been shown that CFSs undergo mitotic
DNA synthesis (MiDAS) before completing mitosis (21).
To this end, we evaluated the number of chromosomal gaps
and breaks that incorporated EdU in metaphase spreads, in
the absence and presence of low dose APH (Figure 4C, D
and Supplementary Figure S4B). In accordance with pre-
vious studies, the majority of gaps and breaks were EdU
negative in untreated conditions (21) (Figure 4D). However,
we observed that ATRX knock down (KD) increased the
number of EdU positive (MiDAS positive) gaps and breaks
(Figure 4D), and that APH treatment resulted in a marked
increase in this phenotype in comparison to ATRX profi-
cient cells (Figure 4D). Finally, we investigated the effects of
ATRX deficiency specifically on FRA16D, one of the CFSs
with the highest propensity to break. We observed that de-
pletion of ATRX in untreated conditions led only to a mild
increase in FRA16D fragility, while addition of low dose of
APH resulted in a significant increase in FRA16D fragility
(Figure 4E and F). Together these data indicate that the
increased breaks and gaps observed in metaphase spreads
upon ATRX depletion occur at CFSs and that ATRX is
important for maintaining CFS stability.
Next, we investigated the cellular consequences of ATRX
deficiency in relation to CFS instability. First, we observed
that ATRX depletion combined with APH increased the
number of cells with multiple 53BP1 nuclear bodies (N.B.)
in G1 cells (Figure 5A and B). These nuclear structures are
associated with CFS instability (52), and their induction
suggests that the CFS instability provoked by ATRX de-
pletion remains unresolved upon entry into the next cell cy-
cle. Remarkably, we observed that ATRX frequently local-
izes to 53BP1 N.B. in G1, which supports a potential role
of ATRX in modulating the repair of these genomic sites
(Supplementary Figures S5A and B). In concordance with
the above, ATRX KD led to an increase in the number of
micronuclei, a phenotype that was also exacerbated byAPH
treatment (Figure 5C andD), further substantiating the im-
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Figure 3. ATRX associates with chromatin under conditions that induce CFS expression. (A) IF analysis of ATRX (green) in G2 cells. HeLa cells were
treated with DMSO or APH (0.2 M) for 20 h, and G2 cells were selected based on DAPI profile. Representative images are shown. (B) Analysis of
the number of ATRX and FANCD2 foci across the cell cycle. HeLa cells were incubated with DMSO or APH (0.2 M) for 20 h and EdU (20 M) was
incorporated for the last 30min. Analysis was performed using quantitative image-based cytometry (QIBC).DAPI andEdUprofiles were used to determine
cell cycle stages (G1, early, mid and late S and G2). Z-stack images were acquired to determine the number of foci per cell. The average number of ATRX
foci per cell in each stage is illustrated in the box plots for vehicle (blue) or after APH treatment (green). Data shown corresponds to the average of >700
cells per condition. Means, SDs, maximum and minimum values are indicated. Significance was evaluated with unpaired t-test ****P ≤ 0.0001. (C) IF
analysis for colocalization of ATRX (green) and FANCD2 (red) in G2 cells. HeLa cells were treated with DMSO or APH (0.2 M) for 20 h. Two different
colocalization patterns are indicated: complete foci overlap (middle row and indicated by white arrows) and adjacent foci (bottom row). Representative
images are shown. Selected regions are magnified. (D) Quantification of FANCD2 and ATRX colocalizing foci per G2 cell. Data shown correspond to
biological duplicates of 300 cells per condition. Means and SDs are indicated. Significance of the total number of colocalizing foci was evaluated with
unpaired t-test ****P ≤ 0.0001. (E) Quantification of the percentage of FRA16D loci colocalizing with ATRX foci. HeLa cells were treated with DMSO
or APH (0.2 M) for 20 h and arrested at G2. Data shown corresponds to biological triplicates of 300 cells per condition. Means and SDs are indicated.
Significance was evaluated with unpaired t-test. *P ≤ 0.05. (F) Example of ATRX IF (red) colocalizing with FRA16D (green) in G2 cells. Selected regions
are magnified.
portance of ATRX to maintain genomic stability. Together,
these results reveal that, while ATRX depletion alone ren-
ders a mild increase in CFS instability, its absence renders a
dramatic increase in CFS fragility upon replication pertur-
bation, indicating that the mechanisms to maintain CFSs
are compromised.
ATRX functions with DAXX in CFS stability maintenance
Our data indicates that ATRX plays a role in CFS stabil-
ity maintenance. However, the observed increase in CFS
expression is most commonly a consequence of increased
RS during S-phase. To address whether ATRX deficiency
induces RS, we assessed the rate of EdU incorporation in
ATRX KD cells, in the presence and absence of APH. We
observed that DNA replication was unperturbed in ATRX
depleted cells, and that the cell cycle profile was also unaf-
fected (Supplementary Figures S5C andD), suggesting that
the impact of ATRX deficiency on CFS stability does not
occur due to a global increase ofRS. Furthermore, the num-
ber of FANCD2 foci in G2 was unchanged upon ATRX
KD, in normal conditions or uponRS (Supplementary Fig-
ures S6A and S6B), indicating that ATRX depletion does
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Figure 4. Effects of ATRXdepletion on CFS stability. (A)Metaphase spreads of HeLa cells to assess CFS instability upon depletion of ATRX compared to
transfection with control siRNAs. Two days post-transfection, cells were treated with DMSO or APH (0.4 M) for 20 h. Representative images are shown.
Arrows indicate representative gaps and breaks. (B) Quantification of gaps and breaks inmetaphase spreads of HeLa cells transfected with indicated siRNA
and treated as in (A). Average of 40 spreads per condition are shown. Mean and SEMs are indicated. Significance was evaluated with unpaired t-test **P
≤ 0.01;****P ≤ 0.0001. (C) Evaluation of MiDAS upon depletion of ATRX compared to transfection with control siRNAs. HeLa cells were treated
with DMSO or APH (0.4 M) for 20 h. Arrows indicate representative images of EdU-positive breaks. (D) Quantification of EdU-negative and -positive
(MiDAS) gaps and breaks in metaphase spreads of HeLa cells transfected with the indicated siRNAs and treated as in (C). Data shown corresponds
to the average of 60 spreads per condition from two biological replicates. Mean and SEMs are indicated. Significance was assessed with unpaired t-test.
n.s. >0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001;****P ≤ 0.0001. (E) Evaluation of FRA16D fragility upon depletion of ATRX compared to transfection
with control siRNA. HeLa cells were treated with APH (0.4 M) or DMSO for 20 h. Representative images of intact and broken FRA16D are shown. (F)
Quantification of the frequency of FRA16D fragility in metaphase spreads of HeLa cells transfected with the indicated siRNAs and treated as in (E). Data
shown corresponds to biological triplicates of at least 120 FRA16D scored loci. Means and SDs are indicated. Significance was evaluated by Chi-square
test. n.s. >0.05; *P ≤ 0.05. ATRX depletion was verified by WB or IF in all the experiments performed.
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Figure 5. Consequences of ATRX depletion on markers of genomic instability. (A) 53BP1 N.B. in G1 cells were determined by Cyclin A (green) and 53BP1
(red) IF stainings in HeLa cells transfected with the indicated siRNAs. Two days post-transfection, cells were treated with DMSO or APH (0.2 M) for
20 h. (B) Quantification of analysis from (A). Cyclin A negative cells were selected as G1 cells. Data correspond to biological duplicates of >200 cells per
condition. Means and SDs are indicated. Significance was assessed by unpaired t-test. n.s P > 0.05; *P ≤ 0.05; **P ≤ 0.01. (C) Evaluation of micronuclei
formation. HeLa cells were transfected with the indicated siRNAs. Two days post-transfection, cells were treated with DMSO or APH (0.2 M) for 20 h.
Red arrows indicate micronuclei in representative images. (D) Quantification of cells with micronuclei as described in (C). Data correspond to biological
triplicates of >500 cells per condition. Means and SDs are indicated. Significance was assessed by unpaired t-test. *P≤ 0.05; **P≤ 0.01. ATRX depletion
was verified by WB or IF in all the experiments performed.
not lead to a higher number of stressed CFSs. Together,
our data indicate that ATRX is not affecting the number
of stressed CFSs and suggest that, instead, ATRX plays a
role in the resolution of challenged CFSs.
To elaborate on this, we assessed the influence of
FANCD2 on the role of ATRX in CFS stability. FANCD2
depletion resulted in a reduced number of ATRX foci in
G2 cells, suggesting that formation of ATRX foci is par-
tially dependent on FANCD2 (Supplementary Figure S6C–
E). Furthermore, we observed that the number of 53BP1
N.B. in G1 induced by APH upon depletion of ATRX and
FANCD2 together was not exacerbated compared to deple-
tion of FANCD2 alone (Figure 6A and Supplementary Fig-
ure S6F). These results suggest that ATRX and FANCD2
function within a common pathway to limit CFS fragility,
with FANCD2 plausibly functioning upstream of ATRX.
ATRX, together with DAXX, forms a chromatin remod-
eling complex that facilitates DNA repair processes, such as
homologous recombination (53).We therefore sought to es-
tablish whether the role of ATRX at CFSs requires DAXX.
Interestingly, DAXX formed foci upon treatment with low
dose of APH, which displayed complete colocalization with
ATRX foci (Supplementary Figure S6G). Moreover, the
formation of DAXX foci across the cell cycle highly resem-
bled the pattern observed for ATRX and FANCD2, being
higher in APH treatment compared to control at all stages
of the cell cycle, with the peak number of foci in late S
and G2 (Supplementary Figure S6H and 3B). To determine
whether this translates to a role for DAXX in the function
of ATRX in CFSs, we first assessed the capacity to form
foci for either factor in the absence of the other. Depletion
of DAXX resulted in complete abrogation of ATRX foci
formation upon APH treatment, while depletion of ATRX
did not impair the formation of DAXX foci, suggesting that
DAXX is required for ATRX recruitment to CFSs (Fig-
ure 6B). Accordingly, depletion of DAXX induced 53BP1
N.B. in G1 in response to APH, similar to ATRX KD,
whereas additional depletion of ATRX did not exacerbate
this phenotype (Figure 6C and Supplementary Figure S6I).
Together, these results indicate that the function of ATRX
in regulating CFS stability is dependent on DAXX.
DISCUSSION
The repercussion of CFS fragility on genomic stability ren-
ders these regions of indisputable importance in human
health and disease. It has become evident that cells have
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Figure 6. ATRX regulates CFS stability in a DAXX-dependent manner. (A) Quantification of 53BP1 N.B. in HeLa cells transfected with the indicated
siRNAs. Two days post-transfection, cells were treated with DMSO or APH (0.2 M) for 20 h. Cyclin A negative cells were selected as G1 cells. Data corre-
spond to three biological replicates of>600 cells per condition. Means and SDs are indicated. Significance was assessed by unpaired t-test. n.s.>0.05;***P
≤ 0.001;****P ≤ 0.0001. (B) IF analysis of ATRX (green) and DAXX (red) in G2 cells. HeLa cells were transfected with the indicated siRNAs and two
days post-transfection, cells were treated with APH (0.2 M) for 20 h. Representative images are shown. (C) Quantification of 53BP1 N.B. in HeLa cells
transfected with the indicated siRNAs. Two days post-transfection, cells were treated with DMSO or APH (0.2 M) for 20 h. Cyclin A negative cells
were selected as G1 cells. Data correspond to biological triplicates of >600 cells per condition. Means and SDs are indicated. Significance was assessed by
unpaired t-test. n.s. >0.05;****P ≤ 0.0001. ATRX, FANCD2 and DAXX depletion was verified by IF in all the experiments performed.
developed complex mechanisms to maintain CFS integrity.
In this study, we performed the first quantitative MS-based
global analysis to identify proteins recruited to CFSs un-
der conditions when they are prone to breakage. With our
strategy, we were able to quantify abundance changes of
numerous proteins with known functions in CFS mainte-
nance. We also identified other factors which, to date, have
not been implicated in CFS integrity. Among those, we val-
idated and characterized the function of the chromatin re-
modeler ATRX at CFSs. Our study revealed that ATRX
indeed is critical for CFS stability, rendering this resource
valuable to identify new proteins that safeguard these cru-
cial genomic regions.
We identified over 200 potential CFS interacting pro-
teins in our MS screen. Among the most enriched were
FANCD2 and its constitutive interactor FANCI, thus val-
idating our method. Interestingly, we also identified many
proteins from the Fanconi Anemia core complex, which are
important for the activity of the FANCD2–FANCI com-
plex upon DNA damage (20). In accordance with current
models of CFS maintenance, bioinformatics analysis in-
dicated that our dataset contained a large subset of pro-
teins involved in DNA repair, chromosome organization
andDNA replication. Indeed, proteins involved inDNA re-
pair were among the most highly enriched, many of which
have already been reported to participate in CFS repair, in-
cluding the MRN complex (MRE11, RAD50 and NBN),
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BRCA1 and its constitutive partner BARD1, and the BTR
complex (BLM, TOP3A and RMI proteins) (16,40–43).
These results validate our strategy to identify novel genome
caretakers that remain to be characterized within the con-
text of CFS stability.
Among the novel factors identified in our CFS pro-
teome, we focused on the validation and characterization of
ATRX. ATRX has been involved in several genome main-
tenance and repair pathways by which it may contribute
to maintain CFS stability. First, ATRX has been reported
to function in the resolution of R-loops at telomeres (50).
Given that replication-transcription collision comprises a
risk factor for CFS stability, this could be one of the mech-
anisms by which ATRX deficiency leads to increased CFS
fragility. Second, it has been shown that upon laser irra-
diation induced DSBs, the chromatin remodeling complex
ATRX/DAXX deposits H3.3 to facilitate homologous re-
combination, an important pathway that regulates CFS sta-
bility (53,54). Finally, a recent study shows that ATRX de-
ficiency promotes G-quadruplexes stabilization and DNA
damage in glioblastoma cells (55). CFSs are regions prone
to form secondary structures; therefore G-quadruplexes
stabilization caused by ATRX deficiency could also con-
tribute to CFS instability. In this study, we found that
ATRX, together with DAXX, is indeed required for CFS
stability, and particularly when the integrity of these regions
is challenged by RS. We observed that ATRX localizes to
some CFSs together with FANCD2 in G2 cells, and that
this phenotype is increased upon conditions that challenge
CFS stability, such as mild RS upon treatment with a low
dose of APH.
Induction of RS could indeed account for the increased
CFS fragility. In this regard, studies have found that ATRX
may play a role in the RS response, since knock-out (KO)
cells have shown decreased viability and DNA replication
(56). However, in our system, loss of ATRX did not lead
to increased RS or perturbed the cell cycle upon efficient
transient depletions. Importantly, we did not observe an in-
crease in FANCD2 foci upon ATRX depletion. This sug-
gests that ATRX does not directly increase RS and does
not contribute to induction of CFS stress. It is tempting
to speculate that the accumulation of genomic alterations
due to CFS instability over several cell cycles may cause the
more severe phenotypes observed in ATRX KO cells such
as replication defects and decreased viability (56).
However, the increased incidence of DNA breaks, and
other hallmarks of CFS instability, such as MiDAS, 53BP1
N.B. and micronuclei upon depletion of ATRX indicates
that this protein functions in the downstream repair of dam-
aged CFSs. Indeed, our data indicates that, when present
at the same CFS, ATRX and FANCD2 probably function
within the same pathway that attempt to repair stressed
CFSs prior to mitotic entry. Specifically, the reduction of
ATRX foci upon FANCD2 depletion and lack of exac-
erbated phenotype upon double depletion of these two
factors, indicate that ATRX may function downstream of
FANCD2.
Unlike FANCD2, however, ATRX only functions in a
subset of stressed CFSs, presumably those undergoing a
particular repair process for which ATRX is necessary. This
is evident with the percentage of FANCD2 foci colocaliz-
ing with ATRX which is around 10%. Our data indicate
that ATRX regulates CFS stability in a DAXX-dependent
manner, which may favor the view that the main molecular
mechanism involved is the deposition of H3.3 histones to
facilitate DSB repair by homologous recombination. How-
ever, it remains to be clarified whether the role of ATRX
limiting R-loops or G-quadruplexes is DAXX-dependent.
Compromised ATRX function is the underlying cause of
a rare neurodevelopmental syndrome (Alpha thalassemia
retarded X-linked), a phenotype also typical of other dis-
orders associated with increased fragile site stability, in-
cluding Jacobsen syndrome (increased FRA11B breakage)
(57). On the other hand, mutations in ATRX are strongly
associated with pediatric glioblastoma (58). Importantly,
our data places CFS instability as a potential source of
genomic instability that could partially explain these and
other pathologies associated to ATRX deficiency.
Here, we have presented a global proteomics analysis of
CFSs and the identification of ATRX as a novel regulator
of CFS stability. We believe that the presented proteomics
characterization of CFSs provides a valuable resource to
identify new proteins that function in the maintenance of
these poorly understood regions of the human genome.
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